• NEWS . 04 Jan 2021
  • Atorvastatin and ticagrelor combination therapy improved clinical outcomes in STEMI patients

  • A recent study reported that a combination therapy of atorvastatin and ticagrelor is clinically effective and safe for patients with ST-segment elevation myocardial infarction (STEMI), with cardio-renal protective effects observed including improvement in inflammatory markers and reduction of adverse cardiac events. 

    The aim of the study was to evaluate the effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 and interleukin 33 in STEMI patients. Study participants were 84 STEMI patients who underwent emergency percutaneous coronary intervention. They were divided into a control group (n=44; treated with atorvastatin as routine STEMI treatment) and an observation group (n=40; treated with atorvastatin and ticagrelor). 
     
    The study found that after treatment, the control group had significantly better outcomes in terms of clinical indices, including chest pain relief, enzyme levels, duration of reperfusion-associated arrhythmia and depression of the ST segment. Although both groups exhibited improvements in cardiac ultrasound indices, the observation group showed lower left ventricular end-diastolic and end-systolic diameters and higher left ventricular ejection fractions than the control group. 

    Reference:
    Zhang L, et al. Effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 and interleukin-33 in patients with ST-segment elevation myocardial infarction. J Int Med Res 2020;48:300060520959502.